DSIP
Low EvidenceA neuropeptide studied for its role in sleep regulation and stress modulation.
What It Is
DSIP (Delta Sleep-Inducing Peptide) is a nine-amino-acid neuropeptide first isolated from rabbit cerebral venous blood in 1977. When infused into the mesodiencephalic ventricle of rabbits, it induces spindle and delta EEG activity and reduces motor activity. Research has explored DSIP's potential role in promoting delta-wave (deep) sleep, modulating stress responses, influencing circadian rhythms, and interacting with the endocrine system. A double-blind, placebo-controlled study in chronic insomnia patients found higher sleep efficiency and shorter sleep latency with DSIP compared to placebo, though the effects were modest and researchers concluded that short-term DSIP treatment alone is unlikely to provide major therapeutic benefit for chronic insomnia. More recent preclinical work has explored fusion peptide strategies — a 2024 study published in Frontiers in Pharmacology demonstrated that DSIP fused with blood-brain barrier-crossing peptides (DSIP-CBBBP), produced by Pichia pastoris, enhanced sleep-promoting and neurotransmitter-balancing effects in PCPA-induced insomnia mouse models. Animal stroke research has also shown that intranasal DSIP administration over 8 days accelerated recovery of motor functions in focal stroke rat models, with treated animals performing significantly better on rotarod tests. As of April 2026, the FDA announced removal of DSIP from the Category 2 bulk substances list, meaning it may be evaluated by the Pharmacy Compounding Advisory Committee (PCAC) for potential compounding eligibility. DSIP remains a research peptide with no FDA approval for any therapeutic indication.
Regulatory Status
Moved from Category 2 back to Category 1 per HHS announcement February 27, 2026. FDA PCAC will review Emideltide/DSIP (free base and acetate) on July 24, 2026 for potential 503A Bulks List inclusion. Public comment docket FDA-2025-N-6895 open until July 22, 2026.
Effective: February 2026
View FDA SourceWhy Researchers Study It
DSIP attracts research interest because it is one of the few endogenous neuropeptides directly associated with delta-wave sleep induction. Its interactions with multiple physiological systems — stress response, circadian regulation, pain modulation, and endocrine signaling — make it a compelling subject for understanding sleep-related neuropeptide pathways.
Proposed Mechanisms
- Promotes spindle and delta EEG activity when administered to the mesodiencephalic ventricle
- Modulates cortisol and ACTH levels, influencing the hypothalamic-pituitary-adrenal (HPA) stress axis
- Interacts with opioid systems, potentially contributing to analgesic properties
- May influence circadian clock gene expression and melatonin secretion patterns
- Demonstrates neuroprotective effects in ischemic models, possibly via antioxidant pathways
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Human (double-blind RCT) | Chronic insomnia patients | Higher sleep efficiency and shorter sleep latency vs placebo; effects modest — not considered major therapeutic benefit for chronic insomnia | Source |
| Animal (rat) | Focal stroke — intranasal administration | Accelerated motor function recovery over 8 days; significant improvement on rotarod test vs controls | Source |
| Animal (mouse, 2024) | PCPA-induced insomnia — DSIP-CBBBP fusion peptide | Enhanced sleep-promoting effects and neurotransmitter rebalancing via BBB-crossing fusion peptide strategy | Source |
Commonly Discussed Benefits
Safety & Cautions
- Most foundational research is dated (1980s–1990s); modern clinical data is limited
- Mechanism of action not fully elucidated despite decades of study
- Double-blind trial in chronic insomnia showed only modest benefit
- PCAC review scheduled July 24, 2026 (alongside Semax) for potential 503A Bulks List addition; proposed indications include opioid withdrawal, chronic insomnia, and narcolepsy
- Not FDA-approved for any condition
Comparisons
See how DSIP compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Schneider-Helmert D. — Effects of DSIP on sleep of chronic insomniac patients. Neuropsychobiology. 1987 PubMed
- [2] Schoenenberger GA. — DSIP: a review of its functional significance. Trends Pharmacol Sci. 1984 PubMed
- [3] Khvatova EM. et al. — Delta sleep-inducing peptide recovers motor function after focal stroke. Molecules. 2021 PubMed
- [4] Zhang L. et al. — Pichia pastoris secreted DSIP fusion peptide efficacy in insomnia models. Front Pharmacol. 2024 PubMed
Continue Your Research
Track your research notes and set reminders in the companion app.
Related Peptides
CJC-1295
Medium EvidenceA growth hormone releasing hormone analog studied for stimulating growth hormone secretion.
Ipamorelin
Medium EvidenceA selective growth hormone secretagogue studied for targeted GH release with fewer side effects than other GH peptides.
Selank
Medium EvidenceA synthetic peptide analog of tuftsin studied for anxiolytic and nootropic properties.
Semax
Medium EvidenceA synthetic peptide derived from ACTH, studied for cognitive enhancement and neuroprotective effects.